Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: Trading of Cytos shares and convertible bonds temporarily suspended.

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Miscellaneous
Cytos Biotechnology AG: Trading of Cytos shares and convertible bonds
temporarily suspended.

26.01.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

Cytos Biotechnology Ltd holds a Bondholders' meeting today. Trading of
Cytos shares and convertible bonds temporarily suspended.

Schlieren (Zurich), Switzerland, 26 January 2015, - Cytos Biotechnology Ltd
(SIX:"CYTN"; the "Company") holds today a meeting of the Bondholders to
vote on the restructuring proposal for the convertible bonds, as announced
on 6 January 2015. As the outcome of the meeting is unknown und such
outcome may be price sensitive, Cytos has applied with the SIX Swiss
Exchange to suspend trading of Cytos' shares as well as Cytos' convertible
bonds from ten minutes prior to the start of the meeting (i.e. 12.50 CET)
until at least one hour after the outcome of the meeting has been
communicated by Cytos in a media release. The SIX Swiss Exchange has
approved this request.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=KTKONWJAXQ
Document title: Cytos_Press_E_150126

---------------------------------------------------------------------

26.01.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news
archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
             Open Market ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
316091 26.01.2015
 

 


Das könnte Sie auch interessieren: